Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs.
Davies
Simon J C
SJ
Psychopharmacology Unit, School of Medical Sciences, Bristol BS8 1TD, UK. simondavies@apexmail.com
Cooke
Leila B
LB
Moore
Alan G
AG
Potokar
John
J
D014150:Antipsychotic Agents / Q000009:adverse effects*; D006801:Humans; D007859:Learning Disabilities / Q000188:drug therapy*; D007880:Legislation, Drug; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D013881:Thioridazine / Q000009:adverse effects*
D014150:Antipsychotic Agents; D013881:Thioridazine